TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.97
−0.48%Year over year
Reported trailing growth
- Revenue
- +6.1%
- EBITDA
- +5.1%
- EBIT
- +8.7%
- EPS
- +31.2%
- Free cash flow
- +8.8%
- Operating cash flow
- +8.8%
Forward estimates
Based on analyst estimates
- Revenue
- +4.8%
- EBITDA
- +34.3%
- EPS
- +43.4%
Three-year CAGR
- Revenue
- +24.7%
- EBITDA
- -2.1%
- EBIT
- +1.1%
- Net income
- -2.6%
- EPS
- +37.6%
- Free cash flow
- +32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026